{"id":76294,"date":"2026-09-11T23:35:53","date_gmt":"2026-09-11T21:35:53","guid":{"rendered":"https:\/\/inmuno.es\/index.php\/2026\/09\/11\/phenotypic-and-functional-characterization-of-tumor-reactive-t-cells-in-malignant-pleural-effusions\/"},"modified":"2026-09-11T23:35:53","modified_gmt":"2026-09-11T21:35:53","slug":"phenotypic-and-functional-characterization-of-tumor-reactive-t-cells-in-malignant-pleural-effusions","status":"publish","type":"post","link":"https:\/\/inmuno.es\/index.php\/2026\/09\/11\/phenotypic-and-functional-characterization-of-tumor-reactive-t-cells-in-malignant-pleural-effusions\/","title":{"rendered":"Phenotypic and functional characterization of tumor-reactive T cells in malignant pleural effusions"},"content":{"rendered":"<div>\n<p><b>Cancer Immunol Res<\/b>. 2026 Sep 11. doi: 10.1158\/2326-6066.CIR-26-0293. Online ahead of print.<\/p>\n<p><b>ABSTRACT<\/b><\/p>\n<p>Adoptive cell therapy using tumor-infiltrating lymphocytes (TIL) is effective for treating advanced melanoma but requires surgical tumor resection. Malignant pleural effusions (MPE) may provide a more accessible source of tumor-reactive T cells. Synchronously collected MPE, lung metastasis, and blood from a patient with metastatic melanoma were analyzed using high-dimensional flow cytometry, and single-cell RNA\/T cell receptor (TCR) sequencing. TCR reactivity to autologous tumor was tested in vitro. The proliferative and cytotoxic capacity of ex vivo expanded T cells was assessed in vitro. MPE contained a higher fraction of CD3+ T cells compared with tumor and was enriched for effector CD8+ T cells and effector memory CD4+ T cells. Compared with TIL, MPE T cells exhibited lower features of T cell exhaustion and higher cytotoxicity signatures. The clonal repertoire of MPE and tumor highly overlapped, including 62.2% of predicted neoantigen-specific (NeoTCR) clonotypes. MHC class I-restricted reactivity was functionally confirmed in two of four selected NeoTCR clonotypes. MPE T cells demonstrated higher proliferative capacity under high-dose IL-2 expansion relative to TIL and achieved comparable MHC class I-dependent tumor killing. Overall, MPE contains polyclonal, tumor-reactive T cells with favorable functional features, supporting MPE as an accessible source for TIL therapy.<\/p>\n<p>PMID:<a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/42726782\/?utm_source=SimplePie&amp;utm_medium=rss&amp;utm_content=101614637&amp;ff=20260911173553&amp;v=2.20.1\">42726782<\/a> | DOI:<a href=\"https:\/\/doi.org\/10.1158\/2326-6066.CIR-26-0293\">10.1158\/2326-6066.CIR-26-0293<\/a><\/p>\n<\/div>","protected":false},"excerpt":{"rendered":"<p>Cancer Immunol Res. 2026 Sep 11. doi: 10.1158\/2326-6066.CIR-26-0293. Online ahead of print. ABSTRACT Adoptive cell therapy using tumor-infiltrating lymphocytes (TIL) is effective for treating advanced melanoma but requires surgical tumor resection. Malignant pleural effusions (MPE) may provide a more accessible source of tumor-reactive T cells. Synchronously collected MPE, lung metastasis, and blood from a patient &#8230; <a title=\"Phenotypic and functional characterization of tumor-reactive T cells in malignant pleural effusions\" class=\"read-more\" href=\"https:\/\/inmuno.es\/index.php\/2026\/09\/11\/phenotypic-and-functional-characterization-of-tumor-reactive-t-cells-in-malignant-pleural-effusions\/\" aria-label=\"Read more about Phenotypic and functional characterization of tumor-reactive T cells in malignant pleural effusions\">Read more<\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[55,42],"tags":[],"class_list":["post-76294","post","type-post","status-publish","format-standard","hentry","category-cancer-immunology-reserch","category-publicaciones"],"_links":{"self":[{"href":"https:\/\/inmuno.es\/index.php\/wp-json\/wp\/v2\/posts\/76294","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/inmuno.es\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/inmuno.es\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/inmuno.es\/index.php\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/inmuno.es\/index.php\/wp-json\/wp\/v2\/comments?post=76294"}],"version-history":[{"count":0,"href":"https:\/\/inmuno.es\/index.php\/wp-json\/wp\/v2\/posts\/76294\/revisions"}],"wp:attachment":[{"href":"https:\/\/inmuno.es\/index.php\/wp-json\/wp\/v2\/media?parent=76294"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/inmuno.es\/index.php\/wp-json\/wp\/v2\/categories?post=76294"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/inmuno.es\/index.php\/wp-json\/wp\/v2\/tags?post=76294"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}